Bullous Pemphigoid Indication Strategy Report 2026: FcRn, IL-4Rα, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Inclusion Body Myositis Indication Strategy Report 2026: MSTN, TGF-β, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Polymyositis Indication Strategy Report 2026: IFNAR1, JAK1, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Dermatomyositis Indication Strategy Report 2026: IFNAR1, JAK1, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Axial Spondyloarthritis Indication Strategy Report 2026: IL-17A, TNF, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Polymyalgia Rheumatica Indication Strategy Report 2026: IL-6, JAK1, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Giant Cell Arteritis Indication Strategy Report 2026: IL-6, JAK1, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

ANCA-Associated Vasculitis Indication Strategy Report 2026: C5aR1, CD20, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Minimal Change Disease Indication Strategy Report 2026: CD80, IL-13, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Membranous Nephropathy Indication Strategy Report 2026: PLA2R, CD20, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

IgA Nephropathy Indication Strategy Report 2026: APRIL, BAFF, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Warm AIHA Indication Strategy Report 2026: FcRn, CD20, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.